^
Association details:
Biomarker:TIGIT overexpression
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)

Published date:
10/16/2023
Excerpt:
Moreover, among extensive-stage patients with high expression of CTLA4 and/or TIGIT on PBMCs (n=45 patients), the administration of chemoimmunotherapy was associated with improved survival rates as compared to those receiving chemotherapy only (median OS: 14 vs 7.8 months, p=0.005)...CTLA4 and TIGIT are frequently expressed on PBMCs of SCLC patients and are correlated with significant clinical benefit from the addition of anti-PD-L1 inhibitors to first-line chemotherapy.
Secondary therapy:
Chemotherapy